دورية أكاديمية
أعرض في EDS

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer.

التفاصيل البيبلوغرافية
العنوان: CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer.
المؤلفون: Hwang JH; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Seo JH; Dana-Farber Cancer Institute, Boston, MA, USA., Beshiri ML; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA., Wankowicz S; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA., Liu D; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA., Cheung A; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA., Li J; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Qiu X; Dana-Farber Cancer Institute, Boston, MA, USA., Hong AL; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Botta G; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Golumb L; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Richter C; Dana-Farber Cancer Institute, Boston, MA, USA., So J; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Sandoval GJ; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Giacomelli AO; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Ly SH; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Han C; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Dai C; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Pakula H; Dana-Farber Cancer Institute, Boston, MA, USA., Sheahan A; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Piccioni F; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Gjoerup O; Dana-Farber Cancer Institute, Boston, MA, USA., Loda M; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Sowalsky AG; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA., Ellis L; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA; Brigham and Women's Hospital, Boston, MA, USA., Long H; Dana-Farber Cancer Institute, Boston, MA, USA., Root DE; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Kelly K; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA., Van Allen EM; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA., Freedman ML; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Choudhury AD; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Hahn WC; Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA; Brigham and Women's Hospital, Boston, MA, USA. Electronic address: william_hahn@dfci.harvard.edu.
المصدر: Cell reports [Cell Rep] 2019 Nov 19; Vol. 29 (8), pp. 2355-2370.e6.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101573691 Publication Model: Print Cited Medium: Internet ISSN: 2211-1247 (Electronic) NLM ISO Abbreviation: Cell Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Cambridge, MA] : Cell Press, c 2012-
مواضيع طبية MeSH: Androgen Receptor Antagonists/*therapeutic use , Cyclic AMP Response Element-Binding Protein A/*metabolism, Antineoplastic Agents/therapeutic use ; Benzamides ; Cyclic AMP Response Element-Binding Protein A/genetics ; Drug Resistance, Neoplasm/genetics ; Humans ; Male ; Nitriles ; Open Reading Frames/genetics ; Phenylthiohydantoin/analogs & derivatives ; Promoter Regions, Genetic/genetics ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/genetics ; Receptors, Androgen/genetics ; Receptors, Androgen/metabolism
مستخلص: Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients develop resistance or never respond. We find that the transcription factor CREB5 confers enzalutamide resistance in an open reading frame (ORF) expression screen and in tumor xenografts. CREB5 overexpression is essential for an enzalutamide-resistant patient-derived organoid. In AR-expressing prostate cancer cells, CREB5 interactions enhance AR activity at a subset of promoters and enhancers upon enzalutamide treatment, including MYC and genes involved in the cell cycle. In mCRPC, we found recurrent amplification and overexpression of CREB5. Our observations identify CREB5 as one mechanism that drives resistance to AR antagonists in prostate cancers.
(Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.)
References: Nat Genet. 2006 May;38(5):500-1. (PMID: 16642009)
Nat Rev Cancer. 2015 Dec;15(12):701-11. (PMID: 26563462)
Nat Commun. 2016 Nov 29;7:13668. (PMID: 27897170)
Cancer Res. 2017 Feb 1;77(3):753-765. (PMID: 27899381)
Nat Genet. 2015 Nov;47(11):1346-51. (PMID: 26457646)
J Clin Oncol. 2009 Aug 10;27(23):3742-8. (PMID: 19470933)
Nat Commun. 2018 Oct 4;9(1):4080. (PMID: 30287808)
Nature. 2012 Jul 12;487(7406):239-43. (PMID: 22722839)
Genome Res. 2002 Jun;12(6):996-1006. (PMID: 12045153)
Yi Chuan. 2014 Jul;36(7):679-84. (PMID: 25076032)
Bioinformatics. 2012 Mar 15;28(6):882-3. (PMID: 22257669)
Nucleic Acids Res. 2016 Sep 19;44(16):e131. (PMID: 27270079)
Cell. 2009 Jul 23;138(2):245-56. (PMID: 19632176)
BMC Cancer. 2018 Jun 27;18(1):695. (PMID: 29945573)
J Clin Invest. 2003 Dec;112(11):1724-31. (PMID: 14660748)
Mol Cell Proteomics. 2014 Feb;13(2):397-406. (PMID: 24309898)
Eur Urol. 2015 Nov;68(5):795-801. (PMID: 25698064)
Biostatistics. 2007 Jan;8(1):118-27. (PMID: 16632515)
Oncotarget. 2016 Jul 19;7(29):45171-45185. (PMID: 27191986)
Oncotarget. 2016 May 3;7(18):26259-74. (PMID: 27036029)
Genome Biol. 2011;12(4):R41. (PMID: 21527027)
Nat Biotechnol. 2010 May;28(5):511-5. (PMID: 20436464)
Clin Cancer Res. 2018 Sep 1;24(17):4332-4345. (PMID: 29748182)
Cancer Res. 2007 Apr 15;67(8):3663-72. (PMID: 17440078)
Cancer Cell. 2010 Jul 13;18(1):11-22. (PMID: 20579941)
Oncol Lett. 2017 Dec;14(6):8156-8161. (PMID: 29250192)
Clin Adv Hematol Oncol. 2016 May;14(5):316-9. (PMID: 27379691)
Nature. 2015 Apr 16;520(7547):353-357. (PMID: 25830880)
Nat Methods. 2011 Jun 26;8(8):659-61. (PMID: 21706014)
Curr Protoc Mol Biol. 2015 Jan 05;109:21.29.1-21.29.9. (PMID: 25559105)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Nat Commun. 2014 May 30;5:3972. (PMID: 24875621)
Nature. 2009 Nov 5;462(7269):108-12. (PMID: 19847166)
Oncogene. 2013 Nov 28;32(48):5481-91. (PMID: 23708653)
BMC Bioinformatics. 2016 Oct 3;17(1):404. (PMID: 27716038)
J Biol Chem. 1993 Feb 25;268(6):4259-66. (PMID: 8440710)
J Clin Oncol. 2017 Jul 1;35(19):2103-2105. (PMID: 28414609)
Nat Med. 2016 Mar;22(3):298-305. (PMID: 26855148)
Nat Genet. 2018 May;50(5):645-651. (PMID: 29610475)
JAMA Oncol. 2016 Dec 01;2(12):1598-1606. (PMID: 27148695)
Oncotarget. 2017 Mar 21;8(12):19645-19660. (PMID: 28160548)
Clin Cancer Res. 2017 May 1;23(9):2169-2176. (PMID: 28151719)
Nat Biotechnol. 2011 Jan;29(1):24-6. (PMID: 21221095)
Cell. 2015 Nov 5;163(4):1011-25. (PMID: 26544944)
Nat Protoc. 2013 Dec;8(12):2502-15. (PMID: 24263090)
Cell. 2013 Dec 5;155(6):1309-22. (PMID: 24315100)
J Carcinog. 2011;10:20. (PMID: 21886458)
Nucleic Acids Res. 2018 Jan 4;46(D1):D836-D842. (PMID: 29092072)
N Engl J Med. 2012 Sep 27;367(13):1187-97. (PMID: 22894553)
Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210)
JCO Precis Oncol. 2017 Dec 11;1:. (PMID: 32913968)
Cell. 2015 Jul 16;162(2):454. (PMID: 28843286)
Sci Transl Med. 2015 Nov 4;7(312):312re10. (PMID: 26537258)
Cell. 2018 Jul 12;174(2):422-432.e13. (PMID: 29909987)
Cancer Cell. 2017 Oct 9;32(4):474-489.e6. (PMID: 29017058)
PLoS One. 2013 May 21;8(5):e63563. (PMID: 23704919)
Cancer Cell. 2013 Jan 14;23(1):35-47. (PMID: 23260764)
Cell. 2018 Jul 12;174(2):433-447.e19. (PMID: 29909985)
معلومات مُعتمدة: K08 CA188615 United States CA NCI NIH HHS; U01 CA176058 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: CREB5; ORF screen; androgen deprivation therapy; androgen receptor; metastatic castration-resistant prostate cancer; therapy resistance
المشرفين على المادة: 0 (Androgen Receptor Antagonists)
0 (Antineoplastic Agents)
0 (Benzamides)
0 (CREB5 protein, human)
0 (Cyclic AMP Response Element-Binding Protein A)
0 (Nitriles)
0 (Receptors, Androgen)
2010-15-3 (Phenylthiohydantoin)
93T0T9GKNU (enzalutamide)
تواريخ الأحداث: Date Created: 20191121 Date Completed: 20200921 Latest Revision: 20240607
رمز التحديث: 20240607
مُعرف محوري في PubMed: PMC6886683
DOI: 10.1016/j.celrep.2019.10.068
PMID: 31747605
قاعدة البيانات: MEDLINE
الوصف
تدمد:2211-1247
DOI:10.1016/j.celrep.2019.10.068